Table 1.
Controls | LPS | Anti-CD163-dexa plus LPS | High dexa plus LPS | Low dexa plus LPS | |
Body weight | 199 ± 1 | 196 ± 2 | 207 ± 2g | 204 ± 3 | 206 ± 3g |
Weight loss | 11 ± 1 | 14 ± 3 | 22 ± 2a | 23 ± 2a | 21 ± 1a |
Spleen weight | 465 ± 12 | 512 ± 31 | 492 ± 23 | 421 ± 11a | 483 ± 23 |
ALT | 42 ± 3 | 61 ± 16 | 57 ± 20 | 48 ± 9 | 77 ± 31 |
Bilirubin | 3.0 ± 0.0 | 3.3 ± 0.3 | 3.1 ± 0.1 | 3.6 ± 0.4 | 4.0 ± 0.4 |
TNF-α | 0 ± 0 | 26817 ± 9780a | 7208 ± 1977a,c | 16891 ± 4210a | 21583 ± 7117a |
IL-6 | 0 ± 0 | 23075 ± 6758a | 15685 ± 3779a,c,e | 32964 ± 8294a | 25715 ± 4036a |
Body weight (g), body weight loss (g), spleen weight (mg), plasma alanine aminotransferase (U/L), and bilirubin (μmol/L) in controls (n = 8) and in animals injected with LPS 24 h after vehicle (n = 8), anti-CD163mAb-dexa (n = 8), high dose (n = 8) and low dose (n = 8) dexamethasone at termination of study. Plasma TNF-α (pg/mL) and IL-6 (pg/mL) are measured 2 h after saline (controls) or LPS injection.
P < 0.05 vs controls;
P < 0.05 vs low dose free dexamethasone group;
P < 0.05 vs high dose free dexamethasone group;
P < 0.05 vs vehicle. ALT: Alanine aminotransferase; TNF-α: Tumor necrosis factor-α; IL-6: Interleukin-6; LPS: Lipopolysaccharide.